Markets

Eli Lilly Now Rated a “Buy” at Argus Research (LLY)

Pharmaceuticals maker Eli Lilly & Co. ( LLY ) on Wednesday caught a big upgrade from analysts at Argus Research.

The firm said it boosted its rating on LLY from "Hold" to "Buy" on a valuation call. LLY stock has risen 1.7% year-to-date, versus a 6.8% decline in the benchmark S&P 500 Index.

Eli Lilly shares were mostly flat in premarket trading Wednesday.

The Bottom Line

We have been recommending shares of Eli Lilly ( LLY ) since May 4, 2011, when the stock was trading at $35.64. The company has a 5.50% dividend yield, based on last night's closing stock price of $35.64.

Eli Lilly & Co. ( LLY ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Created by Dividend.com


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

LLY

Other Topics

Stocks

Latest Markets Videos